Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis].

Medicina clinica - 15 Jan 2016

Mar Javier, Mar-Barrutia Lorea, Gimeno-Ballester Vicente, San Miguel Ramón

Abstract excerpt

BACKGROUND AND OBJECTIVE: The aim of this study was to measure the cost-effectiveness of the treatment with simeprevir and sofosbuvir in chronic hepatitis C genotype 1 patients with F3-F4 levels of fibrosis, according to the results of the COSMOS trial. MATERIAL AND METHODS: A Markov model was used to estimate the costs and clinical outcomes from the start of therapy. In the model, the progression was simulated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Drug Costs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Cirrhosis

Share to Liver Transplantation

Share to Markov Chains

Share to Quality-Adjusted Life Years

Share to Simeprevir

Share to Sofosbuvir

Source

Identifiers

PMID: 26654558
DOI: 10.1016/j.medcli.2015.09.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis].PMID 26654558Read ↗

Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.Semantic proximity Read ↗

Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.Semantic proximity Read ↗

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.Semantic proximity Read ↗

Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.Semantic proximity Read ↗

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.Semantic proximity Read ↗

Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.Semantic proximity Read ↗

Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.Semantic proximity Read ↗

Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil.Semantic proximity Read ↗

A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.Semantic proximity Read ↗

A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.Semantic proximity Read ↗

Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.